These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 6751921)

  • 1. Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol.
    Kamisaki Y; Wada H; Yagura T; Nishimura H; Matsushima A; Inada Y
    Gan; 1982 Jun; 73(3):470-4. PubMed ID: 6751921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.
    Abuchowski A; Kazo GM; Verhoest CR; Van Es T; Kafkewitz D; Nucci ML; Viau AT; Davis FF
    Cancer Biochem Biophys; 1984 Jun; 7(2):175-86. PubMed ID: 6467175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.
    Kamisaki Y; Wada H; Yagura T; Matsushima A; Inada Y
    J Pharmacol Exp Ther; 1981 Feb; 216(2):410-4. PubMed ID: 7007618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
    O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
    J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.
    Uren JR; Ragin RC
    Cancer Res; 1979 Jun; 39(6 Pt 1):1927-33. PubMed ID: 376113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride.
    Saito T; Ueno T; Sekine T; Kodera Y; Hiroto M; Matsushima A; Nishimura H; Inada Y
    Leukemia; 1997 Apr; 11 Suppl 3():408-9. PubMed ID: 9209407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice.
    Bendich A; Kafkewitz D; Abuchowski A; Davis FF
    Clin Exp Immunol; 1982 Apr; 48(1):273-8. PubMed ID: 7044632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preparation of repeatedly and effectively usable L-asparaginase by a chemical modification].
    Nishimura H; Wada H; Inada Y
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2227-35. PubMed ID: 6548355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
    Yoshimoto T; Nishimura H; Saito Y; Sakurai K; Kamisaki Y; Wada H; Sako M; Tsujino G; Inada Y
    Jpn J Cancer Res; 1986 Dec; 77(12):1264-70. PubMed ID: 3102431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the preclinical antitumor activity and toxicology of L-asparaginase derived from E. coli.
    Charles LM; Bono VH
    Cancer Treat Rep; 1981; 65 Suppl 4():39-46. PubMed ID: 7049380
    [No Abstract]   [Full Text] [Related]  

  • 11. Basis for loss of therapeutic effectiveness of L-asparaginase in sensitized mice.
    Baechtel S; Prager MD
    Cancer Res; 1973 Aug; 33(8):1966-9. PubMed ID: 4578567
    [No Abstract]   [Full Text] [Related]  

  • 12. The chemical modification of E. coli L-asparaginase by N,O-carboxymethyl chitosan.
    Qian G; Zhou J; Ma J; Wang D; He B
    Artif Cells Blood Substit Immobil Biotechnol; 1996 Nov; 24(6):567-77. PubMed ID: 8922226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of an experimental study of the antitumor activity of 1-asparaginase from E. coli and Erw. carotovora].
    Terent'eva TG; Sokolov AB; Navashin SM
    Antibiotiki; 1977 Jan; 22(1):78-81. PubMed ID: 320935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
    Roberts J; Schmid FA; Old LJ; Stockert E
    Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lymphoma 6C3HED by L-asparaginase from Serratia marcescens.
    Boyd JW; Phillips AW
    J Natl Cancer Inst; 1971 Jun; 46(6):1271-6. PubMed ID: 4932428
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
    Park YK; Abuchowski A; Davis S; Davis F
    Anticancer Res; 1981; 1(6):373-6. PubMed ID: 7046623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase.
    Abuchowski A; van Es T; Palczuk NC; McCoy JR; Davis FF
    Cancer Treat Rep; 1979 Jun; 63(6):1127-32. PubMed ID: 466651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of polyethylene glycol-L-asparaginase.
    Ho DH; Brown NS; Yen A; Holmes R; Keating M; Abuchowski A; Newman RA; Krakoff IH
    Drug Metab Dispos; 1986; 14(3):349-52. PubMed ID: 2872037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Asparaginase: discovery and development as a tumor-inhibitory agent.
    Broome JD
    Cancer Treat Rep; 1981; 65 Suppl 4():111-4. PubMed ID: 7049374
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical evaluation of L-asparaginase. Introduction.
    Burchenal JH; Karnofsky DA
    Cancer; 1970 Feb; 25(2):241-3. PubMed ID: 4905151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.